Antiretroviral pharmaceutical expenditure and possibilities for optimization;Gasto farmacéutico en medicación antirretroviral y posibilidades de optimización

Anales de Medicina Interna

Volumn 22, Issue 12, 2005, Pages 575-578

  Tornero Estébanez, Carlos ^a   Cuenca Soria, A ^a   Nolasco Bonmati A ^b   Soler Company, E ^a   Rull Segura, S ^a  

^a HOSPITAL FRANCESC DE BORJA   (Spain)

^b UNIVERSITY OF ALICANTE   (Spain)

Author keywords

Antiretroviral therapy; Drugs cost

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CONSULTATION; CONTROLLED STUDY; DRUG COST; FOLLOW UP; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; TREATMENT FAILURE; TREATMENT RESPONSE; ADULT; COHORT ANALYSIS; ECONOMICS; FEMALE; GENERAL HOSPITAL; MALE; SPAIN; TREATMENT REFUSAL;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG COSTS; FEMALE; HIV INFECTIONS; HOSPITALS, GENERAL; HUMANS; MALE; SPAIN; TREATMENT REFUSAL;

EID: 33644916125     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bozzete SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344: 817-23
2. Yazdanpanah Y. Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrobiol Chemother 2004; 53: 558-561.
3. Tornero C, Cuenca A, Santamaría A, Gil E, Soler E, Rull S. Distribución del gasto farmacéutico en medicación antirretroviral. An Med Interna (Madrid) 2004; 21: 269- 271.
4. Iribarrena, JA, Labarga P, Rubio R, Berenguer J, Miró JM, Antela A, et al. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004) Enferm Infecc Microbiol Clin 2004; 22: 564-642.
5. Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR 3rd, Kimmel AD, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003; 115: 632-41.
6. Schweighardt B, Ortiz GM, Grant RM, et al. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 2002; 16: 2342-44.
7. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 2003; 37: 1541-48.
8. Fagard C, Oxenius A, Guntharf H, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003; 163: 1220-1226.
9. Skiest DJ, Morrow MD, Allen B, McKinsey J, Crosby C, Foster B, et al. It is safe to stop antiretroviral therapy in patients wit preantiretroviral CD4 cell counts > 250 cells/μL. J Acquir Immune Defic Syndr 2004; 37: 3: 1351-1357.
10. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 cells: a controlled, prospective trial. AIDS 2004; 18: 439-446.